SCHEMBL23540433

SCHEMBL23540433

COC(=O)c1ccc(OC(C)=O)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.51
ACHE P22303 2/20 0.50
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.46
MAPK1 P28482 1/20 0.46
GLA P06280 3/20 0.45
GAA P10253 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
ATM Q13315 1/20 0.45
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
ELANE P08246 1/20 0.43
CYP3A4 P08684 1/20 0.43
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
PDK2 Q15119 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28663306 0.87 HSD17B10 (0.53) KDM4EACHELMNAMAPTGLA
SCHEMBL21994466 0.86 ACHE (0.54) KDM4EACHELMNAMAPTMAPK1
SCHEMBL28671619 0.84 CA12 (0.46) KDM4EACHELMNAMAPTGLA
SCHEMBL1179412 0.84 HTT (0.58) KDM4EMAPTMAPK1GLAGAA
SCHEMBL28677234 0.83 KDM4E (0.49) KDM4EACHELMNAMAPTMAPK1
SCHEMBL12332451 0.83 HSD17B10 (0.56) KDM4EACHELMNAMAPTMAPK1
SCHEMBL7952926 0.83 KDM4E (0.70) KDM4EACHELMNAMAPTMAPK1
SCHEMBL1207513 0.83 CA12 (0.66) KDM4ELMNAMAPTMAPK1GAA
SCHEMBL6441929 0.82 KDM4E (0.69) KDM4EACHELMNAMAPTMAPK1
SCHEMBL14700589 0.81 NPC1 (0.54) KDM4EACHELMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof ABBVIE INC. 2024-11-21 US disclosed
CN-116194453-A Protein tyrosine phosphatase degrading agent and method of use thereof 卡里科生命科学有限责任公司 2023-05-30 CN disclosed
WO-2022253250-A1 BRUTON'S TYROSINE KINASE DEGRADER CONTAINING FUSED-RING OR SPIRO-RING 正大天晴药业集团股份有限公司 2022-12-08 WO disclosed
EP-4077319-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF Calico Life Sciences LLC (US) 2022-10-26 EP disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed
WO-2021127586-A1 PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF CALICO LIFE SCIENCES LLC (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383886-A1 Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof PTPN5, PTPN1, PTPN2 KDM4E 406/4885ACHE 4433/4885LMNA 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.